ATTY DOCKET NO. SERIAL NO. FORM PTO-1449 09/961,128 71417/49138 CLOSURE STATEMENT INFORMATIO APPLICANT(S): Kearney et al. ART UNIT: FILING DATE: September 21, 2001 1636 UNITED STATES PATENT DOCUMENTS FIL. DATE SUB DOCUMENT EXAM. CLASS CLASS IF DATE NAME NUMBER INITIAL APPR FOREIGN PATENT DOCUMENTS SUB TRAN YES/NO DOCUMENT NUMBER DATE COUNTRY CLASS CLASS OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.) Alon et al., "Vascular endothelial growth factor acts as a survival CA factor for newly formed retinal vessels and has implications for CO retinopathy of prematurity", Nature Medicine, 1(10):1024-1028 (1995) Falk et al., "A 48-WELL MICRO CHEMOTAXIS ASSEMBLY FOR RAPID AND CB ACCURATE MEASUREMENT OF LEUKOCYTE MIGRATION", Journal of Immunological Methods, 38:239-247 (1980) Fischer et al., "Migration assay for endothelial cells in multiwells", Journal of Immunological Methods", 128:235-239 (1990) Giraux et al., "Modulation of human endothelial cell proliferation and migration by fucoidan and heparin", European Journal of Cell biology, 77:352-359 (1998) Hoffman et al., "Selective inhibition of cell proliferation and DNA CE synthesis by the polysulphated carbohydrate I-carrageenan", Cancer Chemother Pharmacol, 36:325-334 (1995) Kajio et al., "Quantitative Colorimetric Assay for Basic Fibroblast Growth Factor Using Bovine Endothelial Cells and Heparin", JPM 28(1):9-14 (1992) Meyer et al., "A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signaling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases", The EMBO Journal, 18(2):363-374 (1999) 3/30/04

FORM PTO-1449					TY DOCKET NO. SERIAL NO.			
					17/49138	09/	961,128	
INFORMATION DISCLOSURE STATEMENT								
QE JOIO					APPLICANT(S): Kearney et al.			
UNITED STATES PATENT					LING DATE: otember 21, 2001		ART UNIT: 1636	
UNITED STATES PATENT DOCUMENTS								
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)								
CO- CH		СН	Migdal et al., "Neuropilin-1 Is a Placenta Growth Factor-2 Receptor", The Journal of Biological Chemistry, 273(35):22272-22278 (1998)					
CI			Orkin et al., "REPORT AND RECOMMENDATIONS OF THE PANEL TO THE ASSESS THE NIH INVESTMENT IN RESEARCH ON GENE THERAPY", December 7, 1995					
		СJ	Petruzzelli et al., "HEPARIN-BIN AND NECK SQUAMOUS CELL CARCINOMA PROLIFERATION", Head & Neck, 576					
		CK	Sakamoto et al., "Effect of Teco by Choroidal Endothelial Cells", Science, 36(6):1076-1083 (1995)	ogalan Sodium on Angiogenesis In Vitro , Investigative Ophithalmology & Visual				
		CL	Smith et al., Gene delivery systems for use in gene therapy: an overview of quality assurance and safety issues", Gene Therapy 3:1990-200 (1996)					
		СМ	Spyridopoulos et al., Vascular Endothelial Growth Factor Inhibits Endothelial Cell Apoptosis Induced by Tumor Necrosis Factor-α: Balance Between Growth and Death Signals", J. Mol. Cell Cardiol., 29:1321-1330 (1997)					
		CN	Verdier et al., Preclinical Safe Products", Toxicological Science	et al., Preclinical Safety Evaluation of Human Gene Therapy ', Toxicological Sciences 47:9-15 (1999)				
\	/	СО	Yoshida et al., "Differential Endothelial Migration and Proliferation to Basic Fibroblast Growth Factor and Vascular Endothelial Growth Factor", Growth Factors, 13:57-64 (1996)					
Examiner:					Date:			
					3/30/04			

BOS2_428212.1